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n December 2015, the American Gastroenterological Association's Center for GI Innovation and Technology (CGIT) conducted a 1-day workshop to discuss endoscopic ultrasound-guided tissue acquisition (EUS-TA), focusing on the variables that impact outcomes associated with EUS-TA, issues regarding specimen handling, and the exploratory role of EUS-TA in the field of personalized medicine. The content of the industry-sponsored workshop was developed entirely by members of the CGIT. Workshop participants constituted a range of specialists including experts in the fields of therapeutic endoscopy and EUS, cytopathology and histopathology, endoscopic training, and health care policy and thus represented a wide spectrum of stakeholders and attitudes regarding EUS-TA.
The workshop was designed to foster detailed discussions on EUS-TA, including review of published evidence regarding EUS-TA, issues related to specimen handling for routine clinical practice and potential implications for personalized medicine, affirmation of areas of general consensus among the expert participants, and acknowledgement of areas of disagreement or inadequate evidence. Select workshop participants were invited to spearhead a working group to summarize these discussion points, and better define topics requiring further exploration.
The authors forming this working group, which include workshop participants, select CGIT members, and other invited experts, have written this summary for the main purposes of (1) exploring variables that impact EUS-TA; (2) standardizing definitions related to EUS-TA; (3) making recommendations regarding specimen/tissue handling and processing with respect to standard clinical practice, personalized medicine, and research protocols; and (4) discussing future directions for EUS-TA with respect to personalized medicine.
Any specific recommendations within this summary are based on expert opinion, and are not intended to serve as "practice guidelines" for the American Gastroenterological Association. Instead, they reflect a level of confidence among this expert working group that, after reviewing available literature and after group consensus, the desirable effects of any particular recommendation would outweigh any undesirable effects, and that the recommendation would likely be followed by most informed stakeholders. The industry sponsor for this workshop had no contribution or involvement in the drafting or review of this document.
Current Role of Endoscopic Ultrasound Tissue Acquisition of Gastrointestinal and Nongastrointestinal Tumors
EUS-TA, via cytology from fine-needle aspiration (FNA) or fine-needle biopsy (FNB) using specialized core needles designed to obtain histologic specimens, has become a central technique in the assessment of gastrointestinal (GI) and other non-GI malignancies. Common indications for EUS-TA include the diagnosis and staging of pancreaticobiliary and luminal GI malignancy and assessing lymphadenopathy associated with luminal (esophagus, stomach, rectal) GI and lung cancers. In addition, EUS-TA aids in the evaluation of potentially neoplastic GI subepithelial lesions and in the assessment of metastases to the liver, adrenal, and pleural/ peritoneal cavities. Meta-analyses have reported pooled sensitivities of EUS-TA, typically via EUS-FNA, of 85%-89% in identifying a pancreatic malignancy within a solid pancreatic lesion. [1] [2] [3] [4] [5] The presence of underlying chronic pancreatitis has been associated with a reduced ability to identify malignancy because of the difficulty in identifying a discrete lesion to target in this setting. 6, 7 Detection of malignant pancreatic cystic neoplasms via EUS-TA has proven more challenging, with a meta-analysis of 11 studies (totaling 969 patients) using cytology acquired via FNA showing a pooled sensitivity and specificity of 0.54 (95% confidence interval [CI], 0.49-0.59) and 0.93 (95% CI, 0.90-0.95). 8 The diagnostic yield of EUS-TA in these lesions may be increased by specifically targeting the cyst wall or any solid components within the cyst. [9] [10] [11] EUS-TA for the diagnosis of indeterminate biliary strictures via EUS-FNA has shown variable sensitivities of 47%-94%. 12, 13 Similarly, EUS-TA has shown wide variability in assessing lymphadenopathy with diagnostic yields ranging from 54% to 100%. 13 The use of FNB may aid in providing tissue architectural information and allow for immunohistochemical stains necessary for certain diagnosis, such as lymphoma, GI stromal tumors, and metastasis. Diagnostic yields for EUS-FNA in assessing GI subepithelial lesions have ranged from 46% to 93%. 13 Improved diagnostic yields for these lesions have been associated with the use of EUS-FNB.
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Standardized Definitions for Study Outcomes
Understanding and standardizing endpoints is important for endosonographers and cytopathologists evaluating studies reporting on outcomes related to EUS-TA. Diagnostic yield is defined as the percentage of the lesions sampled for which a tissue diagnosis is obtained and specimen adequacy is defined as the percentage of lesions sampled in which the obtained material is representative of the target site and sufficient for diagnosis. Accuracy is defined as the percentage of lesions sampled by EUS-TA techniques that correspond to the final diagnosis at surgical histopathology or clinical follow-up (at least 12 months) for patients with nondiagnostic sampling. 13 Core specimens are obtained typically using FNB needles, may be obtained with FNA needles, and defined by the presence of a tissue sample that allows for histologic and tissue architectural assessment. Future studies evaluating the role of EUS-TA should routinely use these standardized definitions in the study design and protocol.
Variables That Impact Endoscopic Ultrasound-Guided Tissue Acquisition Outcomes
Obtaining an adequate sample and arriving at an accurate diagnosis are fundamental endpoints of EUS-TA.
The most important pitfall associated with this procedure is a low diagnostic yield (false-negative diagnosis) that has the potential to delay patient care and negatively impact patient outcomes. 13 Low diagnostic yield in clinical practice can often be attributed to improper EUS-TA techniques, errors in image recognition, lesion characteristics, and experience of the endosonographer and cytopathologist all contributing to sampling errors. 13, 16, 17 False-negative rates ranging from 4% to 45% have been reported for solid pancreatic masses, 21% to 53% for pancreatic cystic neoplasms, and from 6% to 14% for lymph nodes. 16 Significant efforts have been made in recent years to establish an ideal EUS-TA technique; one that is associated with a high specimen adequacy, diagnostic yield, and accuracy rate and a low adverse event rate (key relevant and meaningful outcomes of EUS-TA) with the minimum number of passes. 13, 18 The ultimate goal is to ensure that endosonographers provide high-quality care to patients undergoing EUS-TA. The most recent quality indicator document for EUS published by the joint American Society for Gastrointestinal Endoscopy and American College of Gastroenterology Task Force identified the following quality indicators related to EUS-TA: (1) diagnostic rate of adequate samples in all solid lesions undergoing EUS-FNA (performance target 85%), (2) diagnostic rate and sensitivity for malignancy in patients undergoing EUS-FNA of pancreatic masses (performance target 70% and 85%, respectively), and (3) incidence of adverse events after EUS-FNA (performance target of acute pancreatitis, <2%; perforation, <0.5%; clinically significant bleeding, <1%). 19, 20 Several variables can impact outcomes associated with EUS-TA and can essentially be categorized as variables related to (1) technique regarding use of suction (wet, dry, and no suction) and stylet, fanning and capillary technique, number of passes; (2) needle type (EUS-FNA vs FNB, needle gauge); (3) endosonographer (training and competency, experience, and volume); (4) cytopathologist (training, experience, and volume) and cytotechnologist expertise in slide preparation and cell block processing; and (5) center (volume and availability of rapid on-site cytopathology evaluation [ROSE] ).
Endoscopic Ultrasound-Guided Tissue Acquisition Technique
Based on the theoretical belief of preventing clogging of the EUS-TA needle lumen by GI wall tissue as the needle traverse this to reach the target lesion, the use of a stylet is advocated by some endosonographers and cytopathologists. However, the routine use of a stylet to improve the diagnostic yield of malignancy or specimen quality cannot be recommended based on high-quality data from randomized controlled trials showing no difference in these endpoints between groups of patients undergoing EUS-FNA with and without a stylet. [21] [22] [23] In addition, air flushing in a slow, controlled fashion seems to be superior to reinsertion of a stylet to express EUS-FNA aspirates, as shown in a randomized controlled trial. 24 The role of suction during EUS-TA is unclear and some endosonographers routinely use suction, tailor the use of suction based on target lesion and/or ROSE, abandon the use of suction or use the capillary technique (slow withdrawal of stylet during passes). A randomized controlled trial compared the diagnostic yield and cytologic characteristics during EUS-FNA of 81 patients with pancreatic masses with and without suction. Overall, samples in the suction groups were associated with a higher diagnostic yield, accuracy, bloodiness, and cellularity. 24 Some data suggest that the use of suction during EUS-FNA of lymph nodes increases bloodiness of specimens without impacting the diagnostic yield. 25 Future trials need to validate the routine use of capillary technique, wet suction technique, and high negative pressure suction during EUS-TA. 15, 26, 27 A randomized controlled trial demonstrated that the use of a "fanning" motion of the needle, in which multiple areas of the lesion are sampled during each pass, was superior to sampling a single region of the lesion per pass. 28 The optimal number of passes required to achieve an optimal sensitivity for malignancy (a quality indicator) during EUS-TA is unclear. Although, a total of 5-7 passes has been suggested in the absence of ROSE, recent studies have shown that a high diagnostic yield of malignancy of >85% can be achieved in solid pancreatic lesions with 3 passes, which may be operator dependent. 1, 13 A recent post hoc analysis of a randomized controlled trial in which patients with solid pancreatic masses were randomized to EUS-FNA with and without ROSE assessed the optimal number of passes. 29 In this study, 4 passes during EUS-FNA detected malignancy with 92% sensitivity (95% CI, 87-95). Tumor size >2 cm was the only variable associated with positive cytology results (odds ratio, 7.8; 95% CI, 1.9-31.6). In masses >2 cm, 4 passes had a sensitivity of 93% (95% CI, 89-96) and 6 passes had a sensitivity of 82% (95% CI, 61-93) for masses 2 cm with no improvement in sensitivity with increasing number of passes. These results showed that in the absence of ROSE, 4 EUS-FNA should be performed to achieve optimal sensitivity in pancreatic masses >2 cm in size and at least 6 passes in lesions 2 cm. In the presence of ROSE, alternative methods of sampling, such as EUS-FNB, should be considered in patients with a high clinical suspicion for malignancy with negative on-site preliminary cytology results. The impact of this algorithmic approach needs to be evaluated in future prospective trials.
Needle Type
Obtaining histologic specimens or core biopsies using EUS-FNB needles has generated a great deal of interest in the field of EUS-TA. Proposed advantages of EUS-FNB over EUS-FNA include the potential for improving diagnostic yield, especially for nonpancreatic lesions and cases with prior nondiagnostic EUS-FNA (salvage technique); improving assessment of tissue architecture; allowing for immunohistochemical stains (required for such diagnoses as autoimmune pancreatitis, GI stromal tumors, metastasis, and lymphoma); and potentially eliminating the need for ROSE resulting in cost savings. 13, 18 Several studies have recently evaluated the role of FNB needles with variable success rates. 15, [30] [31] [32] [33] [34] [35] Different FNB needle designs have been described and include reverse bevel needles, Franseen type needles, fork-tip needles, and needles with an antegrade core trap. A recent multicenter randomized controlled crossover trial compared the diagnostic yield of EUS-FNB with EUS-FNA in patients with pancreatic and nonpancreatic masses. 15 A significantly higher diagnostic yield was noted in the FNB group overall and in patients with nonpancreatic masses with no difference noted between the 2 groups in patients with pancreatic masses. However, a recent meta-analysis showed no significant difference between EUS-FNA and FNB with regards to diagnostic accuracy (overall for all lesions and solid pancreatic masses alone), sample adequacy for pathologic examination, and in the rate of histologic core tissue procurement; however, FNB was associated with a lower number of passes in obtaining a diagnostic sample. . 4 There are limited data comparing these 2 needle gauges during EUS-FNA of other lesions. Comparable outcomes regarding diagnostic performance including procurement of histologic core specimens has been reported in a study comparing EUS-FNB using 25-and 22-gauge core biopsy needles. 36 
Endosonographer Training and Experience and Volume
Training in EUS requires the development of technical, cognitive, and integrative skills beyond those required for standard endoscopic procedures. Current guidelines recommend a minimum of 225 (most for pancreaticobiliary indications) before competency can be determined. 37 Recent studies have defined the learning curves in EUS among advanced endoscopy trainees. [38] [39] [40] In addition, these data also demonstrate that trainees learn at different rates and that a specific case load does not ensure competency in EUS. There are limited data assessing learning curves outside of formal advanced endoscopy training programs, durability of training, and outcomes during independent practice. In most advanced and complex procedures, there is a relationship between procedure volume (operator and/or center) and outcomes but this association is unclear in EUS. As health care continues to transition from a volume-based to a value-based model, it will be increasingly important to deliver care that is efficient and effective.
Role of Cytopathology and Rapid On-Site Evaluation
Close collaboration with cytopathologists and/or cytotechnologists is critical in achieving the endpoints of EUS-TA especially given the advances in this era of personalized medicine. The goal of immediate ROSE is to provide real-time feedback regarding the content and adequacy of EUS-TA specimens to make an accurate diagnosis with the minimum number of passes maximizing the efficiency of the procedure. Another important advantage of ROSE is the appropriate triage of limited specimens for ancillary tests, such as flow cytometry, immunohistochemistry, cytogenetics, and molecular analysis. 13, 18 Conflicting data regarding the clinical impact, time and personnel demands, and lack of appropriate billing of the procedure time with poor reimbursement have all contributed to variability in the use of ROSE during EUS-TA. A recent randomized controlled trial conducted at 3 tertiary care centers that compared EUS-FNA of pancreatic masses with and without ROSE demonstrated no statistically significant difference in the diagnostic yield of malignancy and proportion of patients with inadequate specimens. Although patients undergoing EUS-FNA with ROSE required fewer passes, there was no difference with regards to diagnostic performance and cytopathologic characteristics, number of repeat procedures, and adverse events. The final results were supported by a cost-minimization analysis. 41 Emerging data suggest that ROSE has no significant impact on the final diagnostic yield during EUS-FNB. 15, 34, 42 However, ROSE may have a role at centers with low adequacy rates (<90%) and with less experienced endosonographers. 43 It is clear that with improvements in EUS-TA techniques and the availability of newer EUS-FNB, the role of ROSE will continue to evolve. Another variable that has significant implications for patient management is the interobserver variability among cytopathologists and surgical pathologists with regards to EUS-FNA and FNB specimens. A recent pilot study showed that the interobserver agreement among 4 cytopathologists at the same institution for EUS-FNA cytology specimens of solid pancreatic lesions was moderate (k ¼ 0.45; 95% CI, 0.4-0.49). 44 These results were recently validated in a large multicenter study. 45 Similar to the recent published data in EUS as it pertains to endosonographers, 19, 46 cytopathologists need to also address the issues of learning curves and training, competency, impact of experience and volume on the diagnostic yield of malignancy, along with defining quality metrics for optimal care.
What Is Personalized Medicine and How Can Endoscopic Ultrasound Impact It?
Personalized or precision medicine uses genomic, proteomic, and metabolomic information to prevent, diagnose, and provide customized treatment to patients. When applied to oncology, it aims to maximize the therapeutic effect of the chemotherapeutic regimen while minimizing treatment-related side effects. Specific tumor-related defects are identified so that the optimal targeted therapy can be chosen and provided, similar to the manner in which microbial cultures may be used to target antibacterial therapy. The development of nextgeneration sequencing (NGS) has enabled the assessment of millions to billions of defined segments of the genome with the aim of detecting pathogenic point mutations and insertions/deletions in a cost-and timeefficient manner. 47 This is possible because NGS allows for simultaneous processing of many genes/exons in a single assay compared with the traditional sequential (Sanger) approach. NGS can be performed via diseasetargeted gene panels, whole-exome sequencing, or whole-genome sequencing. 48 The use of targeted gene panels increases the sensitivity for detecting specific lesions compared with the more expensive and laborious whole-exome or whole genome sequencing. For example, NGS allows for "panel testing" of thousands of specific mutations found in genes associated with malignancy, and a large number of tumor panels are available from commercial sources or from individual laboratories. 49, 50 Once specific mutations are identified via NGS, this information may be used to aid in diagnosing and subtyping tumors, to more accurately predict prognosis, and to guide subsequent therapy.
Role of Endoscopic Ultrasound in Personalized Medicine
EUS has the potential to play a major role in the achievement of targeted therapy for certain GI malignancies, and metastases from other primary sites that can be sampled directly by EUS. Given the dual roles of staging and diagnosis, obtaining material for NGS at the time of EUS is practical and cost effective. Until recently, formalin-fixed, paraffin-embedded specimens have been preferred for genomic analyses of tumors. This has led to the belief that EUS-FNB specimens may be necessary or superior for obtaining tissue used for NGS. However, EUS-TA has typically been achieved via FNA and cytology offers several advantages compared with a FNB specimen. Cytologic samples contain a higher concentration of pure tumor cells compared with histology, which are matrix-rich. 51 In addition, alcohol-based fixation improves nucleic acid preservation compared with formalin fixation in histologic specimens. 52 Furthermore, cytologic samples have intact cells, as compared with fragmented cells because of sectioning in histologic specimens.
However, there remains some uncertainty if EUS-TA via FNA will be able to routinely provide adequate material for theranostic studies. One study found only 12.4% of 169 EUS-FNA cell block (cytologic counterpart to histology paraffin embedded tissue) specimens obtained from malignant solid pancreatic masses had adequate cellularity to achieve this goal. 53 Several other studies have found that cytologic samples (smears, ThinPrep slides, and cell blocks) have adequate material for NGS. More recent publications have shown that liquid cytologic samples (FNA rinse material) are excellent and are often superior specimens for personalized medicine in institutions that have validated these types of samples. 47, [54] [55] [56] [57] It is unclear if FNB offers any potential advantages over FNA with respect to acquiring specimens for molecular diagnostics using NGS. A study concurrently assessing FNA and core needle biopsies found improved cellularity, higher tumor fractions, and better NGS metrics with FNA-acquired specimens compared with core samples, suggesting that FNA may be sufficient for NGS. 58 Future research is needed to determine if performing dedicated FNA passes to acquire material for NGS can improve on the originally reported EUS-FNA pancreatic mass cell blocks or if using liquid cytology for NGS can be expanded to more centers. In centers that can only perform NGS on paraffin-embedded specimens, histology specimens acquired by EUS-FNB may be required to achieve this purpose; alternatively, cytologic samples could be sent to major centers that are validated for liquid NGS testing.
Information regarding the amount of cellular material needed to successfully perform NGS is increasingly becoming available. Cytology slides with >5000 cells have been reported to undergo successful NGS 91% of the time compared with only 22% when the cell count was <1000. 49 When 5 ng/mL of DNA was achieved from a slide successful NGS could be performed 93% of the time, compared with only 4% when this concentration was not reached. 49 A recent study found that adequate material could also be obtained from a residual FNA rinse or from FNA-acquired body fluid specimen in all 17 cases when tumor cellularity was 10% in the aspirate. 47 Rinse specimen provided more DNA for analysis (<1 ng/mL to 346 ng/mL) compared with the concurrent cell block or surgical material (<1 ng/mL to 25.8 ng/mL) and NGS from cytology specimen and surgical specimen showed 100% mutation concordance. Liquid specimens are now routinely used clinically at that institution and are actually preferred to surgical paraffin-embedded material for NGS because of superior DNA amounts, decreased preanalytical time, and faster processing and reporting of results (communication). For EUS-FNB specimen prepared by formalin-fixed, paraffinembedded, a 95% success rate for NGS is expected when samples have a tissue volume of 1.2 cm 2 and at least 5 ng/mL of analyzable DNA. 49 Although much of the initial work on EUS-TA has focused on NGS and is the focus of this paper, numerous additional methods, such as RNA and microRNA sequencing, [59] [60] [61] [62] use of fluorescence in situ hybridization, 63, 64 identification of protein and immune markers, the creation of tumor organoids, [65] [66] [67] [68] and low cost whole-exome sequencing are emerging. Of these methods, the ability to create organoids, which are in vitro 3-dimensional tissue models, is particularly promising. Tumor organoids can be rapidly generated from tissue typically acquired via surgical resection. Organoids can simulate the full spectrum of a patient's tumor, including stromal elements believed to be responsible for chemotherapy resistance. In surgically unresectable patients, the creation of human pancreatic ductal adenocarcinoma organoids at the time of tissue diagnosis could allow them to benefit from precision medicine with individualized treatment. 68 Whether EUS-FNB will offer advantages over EUS-FNA with respect to these methods remains to be determined. Given that organoids are 3 dimensional and incorporate tumor stroma, it seems that FNB would be preferred for the creation of these tissue cultures. Ultimately, it is likely that molecular analysis of EUS-acquired specimen will involve the routine incorporation of several of these methods, including both DNA and RNA techniques, to analyze acquired tumor specimens.
Studies Assessing Endoscopic Ultrasound-Guided Tissue Acquisition for Theranostics
Several studies have assessed the feasibility and utility of extracting DNA from previously acquired cytology specimens, many of which were obtained via EUS-FNA, to aid in targeted treatment of GI and lung cancers as well as melanoma. These studies have primarily focused on the ability to adequately perform NGS, observed mutation rates and affected genes, correlation to results from pathologic specimen, and potential clinical implications.
Solid and Cystic Pancreatic Lesions
Although the use of targeted therapy to treat pancreatic ductal adenocarcinoma is frequently discussed, less than 10% of registered drug interventional trials use a biomarker stratification strategy. 69 A study of 29 patients with ampullary cancer or pancreatic ductal adenocarcinoma whose cytology smears underwent NGS with a panel of 160 cancer genes found 83 pathogenic alterations in 21 genes, with most mutations identified in KRAS (93%), TP53 (72%), SMAD4 (31%), and GNAS (10%). 69 Complete concordance was seen with pathology specimen for pathogenic alterations in KRAS, TP53, and SMAD4. Concurrent TP53 and SMAD4 mutations was associated with aggressive behavior and high rates of metastases, whereas having wild-type status for both TP53 and SMAD4 predicted more indolent behavior with lower metastatic potential and higher rates of response to therapy. Thus, these results provide important prognostic information that can guide subsequent therapy. However, a major challenge is that the most commonly identified mutations with such an approach are rarely actionable and most actionable mutations in pancreatic ductal adenocarcinoma occur quite infrequently. Although primarily used in solid lesions, NGS has been used in cystic pancreatic neoplasms. Recently, fluid from 92 pancreatic cystic lesions was assessed using a novel NGS panel for 39 cancer-related tumor suppressor genes or oncogenes and this information was compared with cyst morphology and cyst fluid cytology and CEA. 70 The authors found that NGS altered the clinical impression in 12% of patients and noted that NGS may allow for a more accurate classification of cysts (mucinous vs nonmucinous) and predict which mucinous cysts are more likely to progress to malignancy. However, this study was limited by the fact that only 18% of patients had a final histologic diagnosis.
In addition to NGS, RNA and microRNA analyses of specimen obtained by EUS-FNA have also been performed. RNA sequencing has been shown to potentially aid in distinguishing adenocarcinoma from benign pancreatic masses 59 and in determining response to chemotherapy. 62 Similarly, microRNA analyses may aid in not only in achieving a diagnosis, but also in predicting prognosis and identifying tumor susceptibility to chemotherapeutic agents in pancreatic ductal adenocarcinomas. 60, 61 Another important recent advance has been the creation of murine and human pancreatic organoids from normal and malignant pancreatic tissue. 65, 66 Organoids developed from pancreatic progenitor and tumor cells are believed to more accurately retain patient-specific tumor/tissue characteristics and can be successfully used to test for drug sensitivity when compared with traditional 2-dimensional tissue culture models. 67 Most recently, a study found the aforementioned pancreatic cancer organoids can be successfully created from tissue acquired during EUS-FNB, avoiding the need for surgically acquired specimen. In total, tumor organoids were created in 84.6% (22 of 26) of patients by obtaining 2 FNB specimens after up to 5 initial EUS-FNA specimen were obtained to achieve a tissue diagnosis. Furthermore, the organoids that were created matched with 2 surgically created organoids and also allowed for successful in vitro drug sensitivity testing in 3 cases. 68 
Rectal Cancer
Biomarker stratified treatment plays an important role in metastatic colorectal cancer, where monoclonal antibody treatments directed against epidermal growth factor receptor have been used. Low rates of effectiveness of these treatments and the lack of benefit from epidermal growth factor receptor mutation testing resulted in the discovery that mutations in KRAS, NRAS, BRAF, and HRAS all predicted poor response to this treatment. A study of 102 patients EUS-FNA of malignant lymph nodes associated with rectal cancer found that 89% had a total of 189 alterations identified in 19 genes. 51 The findings suggested that 42% of patients were believed to contain mutations that would lead to a poor response to anti-epidermal growth factor receptor treatments. From a precision medicine perspective, tumor heterogeneity has been observed in a variety of malignancies including colorectal cancer. The utility of using nodal tissue is unclear because discordant KRAS mutational profiles are seen between primary and peripheral lesions in rectal cancer (caused by intratumoral heterogeneity) in up to 31% of patients. 71 The ideal goal is to evaluate the primary (mucosal site) and the metastatic site (including the liver) and determine if the findings are concordant or not. If not, the objective should be to treat the primary and the metastatic site separately with an appropriate chemotherapeutic agent.
Gastrointestinal Stromal Tumors
Similar to rectal cancer, biomarker analysis can aid in the treatment of gastrointestinal stromal tumors. Specifically, resistance or reduced sensitivity to treatment with imatinib mesylate has been associated with mast/ stem cell growth factor receptor Kit gene (KIT) mutations in exons 9 and 17 or mutations in platelet-derived growth factor receptor A (PDGFRA) exon 18. In addition, lesions that are wild-type for either KIT or PDGFRA mutations seem to also have reduced response rates. Thus, knowledge of the frequency of KIT and PDGFRA alterations can aid in determining if imatinib mesylate should be used. Recently, using DNA derived from the cytology smears of 36 patients with a gastrointestinal stromal tumor, NGS using a customized panel looking for select mutations in KIT and PDGFRA was performed. 72 Mutations in KIT and PDGFRA were found in 68% and 15% of patients, respectively. Imatinib sensitivity based on the mutation profile was estimated at only 68%. In the 24 patients with available surgical pathology, the concordance rate for mutations identified between paired cytology and surgical specimen was 96%. These data suggest that EUS-FNA can aid in the selection of the choice of therapy for these lesions.
Lung Cancer
EUS-TA has been used to assess mediastinal adenopathy or identify adrenal metastases in patients with lung cancer. Similar to the aforementioned studies, pathogenic alterations were found in 85% of patients (25 of 28) using a 50-gene NGS panel of samples acquired from adrenal metastases. 73 At least 1 alteration that has been linked to available or developing targeted treatment was identified in half of these cases. In another study, mutations in STK11, the 3rd most frequently mutated gene in lung cancer, were identified in 18.2% of 22 patients with adrenal metastases from lung cancer. 74 The information regarding the frequency of this mutation may aid in future drug development and provide prognostic data regarding resistance to existing therapies.
Recommendations Regarding Tissue Handling
Clinical Practice
Pathologic specimens are processed in anatomic pathology laboratories (surgical pathology and cytopathology) based on collection technique and specimen labeling. Although common knowledge for pathologists and the laboratory, the clinical team and device manufacturers may not be aware of these critical differences and the subsequent impact on diagnostic material. For instance, a "core biopsy" that is obtained via EUS is processed by different personnel and with different techniques than FNAs and other cytologic specimens. Tissue processing for a core biopsy includes gross examination of the visualized core, formalin fixation, processing, and paraffin embedding. Cytologic processing includes concentration and filtration techniques by specialized personnel to allow cellular material to be evaluated in liquid specimens. Although smears and cell blocks are commonly used in cytology specimens, rinse of FNA material into saline or other alcohol-based fixatives also allows for liquid concentration techniques to maximize the diagnostic yield. Formalin fixation prevents full cytologic processing.
Core biopsy and other tissue specimens are grossed and processed in surgical pathology by pathology assistants and histotechnologists. Any cellular material that is microscopic or too small to grossly filter into tissue paper is not seen by the pathologist following processing of the tissue into a final glass slide stained tissue section. Likewise, a specimen that is actually obtained via FNA technique but called a "core biopsy" is not handled and processed by the appropriate laboratory and may diminish diagnostic yield, and additional molecular testing for personalized diagnostics. Knowledge of specimen handling and labeling and impact on laboratory processing is critical for maximum diagnostics and ancillary studies. Manufacturer advertising of collection devices should also be cognizant of these distinctions to avoid improper handling and potentially unintentional diminished diagnostic yield.
Personalized Medicine
Specimen handling is critical for personalized medicine. Every patient procedure with specimen acquisition should be optimized to provide maximum value for both diagnostics and potential therapeutics, including ancillary and molecular testing. Preventing the need to perform additional patient procedures to obtain sufficient diagnostic material for molecular testing is cost effective and value based, and essential to shorten the time to initiate therapy in advanced-stage disease.
The most important component of specimen handling for personalized medicine and diagnostics is communication between the endosonographers, oncologists, and the pathology team. Increasingly EUS is used to obtain material from metastases or primary malignancies for diagnosis and molecular studies for personalized medicine. Proper specimen handling, maximization of all tissue/cytology specimens available, and prompt triage of confirmed diagnostic material to the various additional laboratories for timely testing (immunohistochemistry, fluorescence in situ hybridization, NGS, cytogenetics, and so forth) is accomplished by the pathology team best when it is known at the time of specimen receipt by documentation on the specimen requisition or order or communicating directly with the pathologist during ROSE. Although tissue biopsy is often considered to be the best sample for molecular testing, cytologic specimens can be used and are sometimes considered superior because of improved quality and quantity of analyzable DNA. Obtaining both cytologic and surgical specimens during a single procedure allows for optimal triage and handling of all specimen types to improve diagnostic yield and molecular testing.
Pathology laboratories need to examine their processes to optimize sample processing under the assumption that all samples may potentially need future molecular testing. Some laboratories have changed their standard procedures in cytology and surgical pathology to improve their diagnostic yield and allow for future molecular testing, both in the short and long term. Personalized diagnostics has dramatically increased over the last several years, and will continue to do so. Communication and process changes for the entire clinical team, and education on which specimen can be used for testing, will have a tremendous impact on patient care.
Future Directions
Future studies need to continue to focus on establishing an ideal EUS-TA technique; one that not only achieves the key relevant and meaningful outcomes of EUS-TA in current clinical practice but also in the expanding field of personalized medicine. The stage is set for future high-quality multicenter prospective studies to clarify the role of EUS-FNA/B sampling for all tissue types for diagnostic and theranostic purposes. In the future, techniques to maximize the cell density within acquired samples will potentially improve NGS analyses. Advances in NGS may allow for the ability to detect additional rearrangements and copy number abnormalities in addition to currently identified mutations. The development of focused panel testing for specific tumors will potentially allow further tumor subtyping and may aid in the development of future tumor-specific targeted therapies while reducing processing times and cost. Such advances may also aid in selection of appropriate patients for clinical trials. Eventually, with continued improvements in identifying and concentrating circulating tumor cells and further reductions in the DNA content necessary to achieve successful analysis, NGS may be achieved from a peripheral blood specimen in lieu of traditional cytology/histology specimens. Indeed, the potential for identifying circulating tumor cells in pancreatic cancer via EUS-guided portal vein sampling 75 or from peripheral blood specimens 76 has already been demonstrated, as has the potential for performing NGS from single circulating tumor cells. 77, 78 
Summary and Conclusions
This paper serves to (1) summarize the current knowledge regarding outcomes and variables of EUS-TA for routine clinical practice, (2) put forth standardized definitions with respect to EUS-TA that may be used for future studies, (3) explore the role of EUS-TA for personalized oncologic care, and (4) provide recommendations regarding tissue handling of EUS-TA specimens for routine clinical practice and for centers engaging in personalized medicine.
EUS-TA clearly plays a vital role in oncologic care. Although outcomes of EUS-TA for standard clinical diagnostics seem well established, there are variables that may impact these outcomes and the optimal EUS-TA methods are not universally standardized. Interest in personalized oncologic care seems to be gaining in popularity. EUS-TA has the potential to play an important role in guiding personalized care. However, this area is in its infancy, and the processes to optimize EUS-TA for theranostic purposes remain to be fully delineated. Tissue handling is an important and complex process with variables based on sampling technique and labeling. It is imperative for all involved clinical stakeholders (endosonographers, pathologists, oncologists) to approach EUS-TA in an inclusive and multidisciplinary format, and remain abreast of advances that may impact EUS-TA for both clinical diagnostics and theranostics.
